BioClinica Shapes Global Industry Discussion At Upcoming Events

NEWTOWN, Pa., Oct. 3, 2013 /PRNewswire/ -- BioClinica^®, Inc. a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in, and speak at more than a dozen upcoming national and international industry conferences in October, November, and December. BioClinica experts will discuss industry trends, present scientific findings, and demonstrate the company's suite of technologies and solutions at the following events:

(Logo: http://photos.prnewswire.com/prnh/20130403/PH87647LOGO)

American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting
October 4 – 7, 2013
Baltimore, Maryland
The ASBMR 20132 Annual Meeting will feature outstanding scientific programs and showcase the latest in research, technology and treatment in bone and mineral science. In addition to the speaker sessions, attendees can also take part in poster session tours lead by prominent scientists.

Senior Vice President of Medical Affairs Colin G. Miller, Ph.D. F.I.C.R, CSci, will attend the event and present a scientific poster titled "Using Body Composition Phantoms to Validate Performance of Dual Energy X-Ray Absorptiometry (DXA) Instrument."

Phacilitate Boston Leaders' Forum 2013
October 16 – 18
Boston Massachusetts
The 12th Annual Phacilitate Leaders' Forum brings historical west and east coast conferences together for one exciting event. The result is a unique blend of specific therapeutic area coverage combined with overall strategic research and development insight from pharma and biotech decision makers, as well as key external stakeholders. In addition to plenary sessions, the conference will include three individual forums focused on Metabolic, Oncology, and Autoimmune and Inflammatory therapeutic areas.

Chief Medical Officer Michael O'Neal, MD will deliver a presentation at the Oncology Forum and Senior Vice President of Medical Affairs Colin G. Miller, Ph.D. F.I.C.R, CSci, will speak at the Metabolic Forum.

BioClinica is a Gold Sponsor of this event and will have representatives available to discuss the company's Imaging and Cardiac Safety solutions.

American College of Rheumatology Annual Meeting
October 25 – 30, 2013
San Diego, California
The American College of Rheumatology annual meeting will feature over 100 classroom-style sessions designed for comprehensive instruction and in-depth discussions with respected professionals with specialized expertise. The event will also feature guided poster tour led by experts in the field.

Senior Vice President of Medical Affairs Colin G. Miller, Ph.D. F.I.C.R, CSci, will attend the event and is on the invitation-only committee on end points in osteoarthritis clinical trials which meets on Wednesday October 25th.

AusBiotech 2013
October 29 – November 1, 2013
Brisbane, Australia
AusBiotech 2013, with the theme 'bio-economy in transition', will focus on the transformation of the Australian industry as it evolves and adapts to current global force shaping the industry. The event has long been valued as the best way to bring together biotechnology experts to share information and support industry growth and prosperity.

A BioClinica representative will be available to discuss the company's Imaging and Cardiac Safety solutions at the UK Trade and Investment booth.

Chinese Course in Drug Development and Regulatory Science (CCDRS)
November 5 – 8, 2013
Beijing, China
Conducted at Peking University Health Science Center, the Chinese Course in Drug Development and Regulatory Science presents a curriculum that emphasizes knowledge integration and experience exchange. Throughout the course attendees will learn a product development process, which is science-based, efficient, and economical, high quality, forward-looking, and reliable.

Vice President of Cardiology Boaz Mendzelevski, MD will contribute to the curriculum with a Cardiac Safety presentation titled "Drug Induced Cardiotoxicity: An Overview of Key Cardiovascular Safety Issues in Drug Development and Regulatory Responses" on November 6^th at 2:30 pm.

IRT 2013 – CBI's 3rd Annual Interactive Response Technologies in Clinical Trials
November 7 – 8, 2013
Philadelphia, Pennsylvania
The first and only meeting dedicated to the use of IVR/IWR systems in clinical trials, CBI's IRT forum provides a unique platform for discussing the latest system capabilities, utilization and management strategies. As clinical protocols become increasingly global and complex in design, IRT's are utilized to increase efficiencies and decrease the costs of conducting clinical trials and managing data. Join the discussion and learn from industry peers as they benchmark best practices and strategies for managing clinical IVR/IWR systems.

BioClinica is a sponsor of this event and will have representatives available to discuss and demonstrate the Trident Interactive Response Technology solution.

6th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 14 – 16, 2013
San Diego, California
Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. The 6th annual CTAD conference will relate experiences from international teams covering every stage of clinical trials in Alzheimer's Disease. From animal models to human trials, CTAD 2013 provides an opportunity to learn about the latest results in drug trials as well as important topics such as internet screening of cognition to recruit for clinical trials, designing drug trials taking into account neuropsychiatric symptoms, down syndrome, as well as ethical issues and methodological considerations. BioClinica is a sponsor of this event.

Vice President and Executive Director Chahin Pachai, PhD, and Medical Affairs Scientist Hui Jing Yu, PhD, will attend the meeting and present the following posters:

• Predictive Value of Baseline Hippocampal Volumes and Brain Amyloid Burden on Atrophy Rates for Predementia Alzheimer's Disease Subjects with Data from Study CN156-018 and ADNI-1
• Comparison of Intracranial Volume Quantification Based on 2D T2* and 3D T1-Weighted MRI Sequences
• Comparison of Boundary Shift Integral and Tensor Based Morphometry to Assess Volume Changes on Whole Brain and Lateral Ventricles – Application to Study CN156-018
• Longitudinal Volumetric Changes in Study CN156-018, as Compared to ADNI-1

Partnerships in Clinical Trials Europe 2013
November 19 – 21, 2013
Vienna, Austria
Booth #203
The 12th annual Partnerships in Clinical Trials Congress will be held in Vienna, Austria. The conference will feature over 150 speakers from large, mid-size and small pharmaceutical companies as well as CROs and vendors covering topics focused on clinical development. Informative plenary and breakout sessions will cover an array of content areas including risk-based monitoring, relationship management, patient recruitment, outsourcing, and vendor oversight. This year's conference will also feature new interactive formats including closed-room discussions, evidence-based briefings, candid interviews, and community forums.

BioClinica is a Passport Sponsor and will have representatives available in booth #203 to discuss and demonstrate the company's Imaging, Cardiac Safety, and eClinical solutions.

34th Annual Meeting of The Japanese Society for Clinical Pharmacology and Therapeutics (JSCPT)
December 4 – December 6, 2013
Tokyo Japan
Translational research and regenerative medicine are among the new fields that need to be explored to meet current and future demands of medicine. The JSCPT has established a theme for the annual meeting that is consistent with the demands of our times: "Clinical Pharmacology for a New Generation." The goal of the meeting is to create socially applicable results discovered through professional discussions about the many different areas of clinical pharmacology. These areas include early-stage exploratory clinical trials, the increased application of pharmacokinetics and pharmacodynamics, the rational prescription of drugs, the selection of clinical trial designs and statistical methodologies, the development of orphan drugs, research ethics, the current status of infectious disease and cancer treatments, and collaboration between industry, government, and universities.

BioClinica representatives will be available to discuss the company's Imaging and Cardiac Safety solutions.

CACO/PBSS Workshop: Safety Pharmacology: Cardiovascular, Hepatic and Renal Safety Evaluations in Drug Development
December 5, 2013
San Francisco, CA
CACO Pharmaceutical & BioScience Society (CACO-PBSS) San Francisco Bay Area is a non-profit professional organization of scientists and other professionals in the life science sector. On December 5^th, BioClinica will sponsor a CACO/PBSS workshop on the topic of Saftey Pharmacology with presentations from Philip Sager, Arie Regev (Eli Lilly), Laurie Tsuruda (BioMarin), Hong Wang (Genentech). BioClinica's Director of Scientific Affairs Jeff Heilbraun will attend the event.

2013 American Society of Hematology (ASH) Annual Meeting
December 7 – 10, 2013
New Orleans, Louisiana
Booth #1902
As the premier hematology event of the year, the ASH Annual Meeting is an invaluable educational experience for all attendees. The meeting features opportunities to grow professionally by learning about the latest clinical updates in research, therapies, and practice strategies through educational and scientific programs.

BioClinica representatives will be available to discuss the company's Imaging and Cardiac Safety solutions in booth #1902.

2013 Cardiac Safety Research Consortium / International Cardio Oncology Society (CSRC/ICOS) Annual Conference Meeting
December 12 – 13, 2013
Washington, DC
The annual CSRC/ICOS meeting promises to be a valuable experience for researchers in the cardiac safety and cardio oncology fields. Vice President of Cardiology Boaz Mendzelevski, MD is a co-chair of the event and will moderate the topic "Detection of Heart Failure and Myocardial Toxicity." Director of Scientific Affairs Jeff Heilbraun will participate in a panel discussion on the topic "Hypertension Associated with Newer Drug Development: The Impact of Anti-angiogenic and Other Therapies."

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions: imaging core lab services including electronic transfer, management, and independent review; cardiovascular safety monitoring including automated ECG, Thorough QT studies,  Holter monitoring, ambulatory blood pressure monitoring and pulse wave analysis; and eClinical solutions for electronic data capture, randomization, clinical trial management, and clinical supply chain forecasting and optimization. BioClinica offers unmatched scientific expertise with a team of respected medical researchers and board certified, sub-specialty trained radiologists, cardiologists, nuclear medicine physicians and oncologists. With more than 28 years of experience and over 3,300 successful trials to date, BioClinica has supported the development of many new medicines through all phases of the clinical trial process. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide comprehensive cardiovascular safety, and eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

SOURCE BioClinica, Inc.